NIKIHealthcare · Biotechnology

NIKI Stock Forecast: Niki Biosolutions, Inc. Price Predictions for 2026-2027

Last close, 7 Oct 2026

$4.65

−6.25% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 11 of 100 as at 7 Oct 2026 — in the weakest quartile.

Market cap

$15.5M

Ticker Nerd rank

11 / 100

Median analyst target

—

Analysts covering

Revenue$0.0

Operating income−$825K

Net income−$311K

Free cash flow−$536K

Quarterly, 8 quarters to 31 Dec 2025 · latest quarter's figure shown

Total return, dividends reinvested

−5.1%

−25.0%

YTD

−56.1%

−77.8%

From 52W high

−80.7%

From 52W low

+1.1%

$24

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

NIKI stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Niki Biosolutions, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 7 Oct 2026

11 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Growth

Volatility

Accruals

Revisions

Issuance

Quality

Value

Momentum

Size (90): Smaller than most of the companies we track.

Momentum (6): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

NIKI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NIKI, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Recent analyst actionsNewest first

Date	Firm	Action	Rating	Target
7 Oct 2022	HC Wainwright & Co.	Initiates	Buy	$8.00
2 Apr 2019	China Renaissance	Initiates	Buy	$22

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NIKI appears on the weeks it earns a place.

Performance

NIKI vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 7 Oct 2026, Niki Biosolutions, Inc. returned −77.8% against +17.4% for the S&P 500, dividends included.

NIKI vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

NIKI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Niki Biosolutions, Inc. (NIKI) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: 2.8×
Price / sales: —
Price / book: 0.2×
EV / EBITDA: 1.6×

Growth & margins

Revenue growth (YoY): —
Earnings growth (YoY): —
Gross margin: —
Operating margin: 0.0%
Net margin: 0.0%

Returns & dividend

Return on equity: −17.1%
Return on assets: −10.0%
Dividend yield: 0.0%

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Niki Biosolutions, Inc. (NIKI) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

Niki Biosolutions, Inc. has a market value of $15.5M and an enterprise value of −$3.8M.
Revenue in the twelve months to 31 Dec 2025: $0.0.
Net income over the same four quarters: −$2.4M.
Free cash flow in the twelve months to 31 Dec 2025: −$929K.
Shares outstanding: 814,375.
Trailing P/E: 2.8×; forward P/E: −1.0× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Niki Biosolutions, Inc. employs 1 people.

Statement figures: company filings via Twelve Data, four quarters to 31 Dec 2025 · market figures as at 7 Oct 2026

Data provided by Twelve Data

Peers

NIKI vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
NIKINiki Biosolutions, Inc.	$15.5M	11
KPTIKaryopharm Therapeutics, Inc.	$14.5M	61
TVRDTvardi Therapeutics, Inc.	$14.7M	32
HINDVyome Holdings, Inc.	$14.3M	64
CLRBCellectar Biosciences, Inc.	$14.3M	27
KTTAPasithea Therapeutics Corp.	$14.8M	15
CTXRCitius Pharmaceuticals, Inc.	$13.8M	21

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Niki Biosolutions, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest NIKI news & analysis

Niki BioSolutions to Participate in the Lytham Partners Fall 2026 Investor Conference

GlobeNewsWire · 25 Sept 2026neutral

Niki BioSolutions announced it will participate in the Lytham Partners Fall 2026 Investor Conference, which is being held virtually on September 29-30, 2026. The company will deliver a webcast presentation and host one-on-one meetings with investors at the conference.

Why it matters — The investor conference participation offers NIKI watchers an opportunity to hear directly from management and engage with the company during one-on-one investor meetings.

Niki BioSolutions Accelerates Its Alzheimer's Disease Testing Pipeline Through Strategic Bioinformatics and Statistical Analysis Partnership with Fios Genomics

GlobeNewsWire · 14 Sept 2026positive

Niki BioSolutions announced a strategic partnership with Fios Genomics to apply advanced multi-omics data analysis and biostatistical expertise to sharpen target and biomarker decisions across its Alzheimer's disease testing platform. The collaboration is intended to accelerate the company's Alzheimer's disease testing pipeline.

Why it matters — A NIKI watcher would care because the partnership bolsters the analytical rigor behind its Alzheimer's testing program, potentially strengthening target and biomarker selection in its development pipeline.

Niki BioSolutions to Participate in H.C. Wainwright's 28th Annual Global Investment Conference

GlobeNewsWire · 8 Sept 2026neutral

Niki BioSolutions, Inc. announced it will participate in the 28th Annual H.C. Wainwright Global Investment Conference, scheduled for September 14-16, 2026, at the Lotte New York Palace Hotel in New York City.

Why it matters — Participation in a major investment conference offers Niki BioSolutions an opportunity to present its business to investors and industry participants.

FAQ

Frequently asked questions about NIKI stock

How does Ticker Nerd's model rank NIKI?

As at 7 Oct 2026, Niki Biosolutions, Inc. ranks 11 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (90 of 100).

What is the NIKI stock forecast for 2030?

No analyst covering Niki Biosolutions, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NIKI are extrapolating price history, which says nothing about the business.

How has NIKI stock performed over the past year?

Niki Biosolutions, Inc. returned -77.8% over the 12 months to 7 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Niki Biosolutions, Inc. do?

Niki BioSolutions, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapeutic products for oncology and infectious diseases.

What is the latest news on NIKI?

The most recent item we track (GlobeNewsWire, 25 Sept 2026): "Niki BioSolutions to Participate in the Lytham Partners Fall 2026 Investor Conference". Niki BioSolutions announced it will participate in the Lytham Partners Fall 2026 Investor Conference, which is being held virtually on September 29-30, 2026. The company will deliver a webcast presentation and host one-on-one meetings with investors at the conference.

Company

About Niki Biosolutions, Inc.

Niki BioSolutions, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapeutic products for oncology and infectious diseases. Its current pipeline includes repurposed drug candidates and small molecules under clinical and preclinical evaluation, with programs aimed at treating neuroblastoma, bacterial infections, and coronavirus disease. The company also works on additional therapeutic assets targeting unmet medical needs across cancer and infectious disease areas. Based in Princeton, New Jersey, Niki BioSolutions operates through subsidiaries and maintains a product portfolio centered on drug development and translational research. Its role in the financial market reflects that of a specialized biotechnology issuer tied to early-stage clinical progress and pipeline advancement.

CEO Mr. Chung Yuen Huen · 1 employees · United States · https://www.aptorumgroup.com